Bristol-Myers Squibb Company (BMY) announced the Japanese Ministry of Health, Labor and Welfare has approved Opdivo (nivolumab) for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy. Opdivo has now been approved for six indications in Japan.
The approval is based on the results of ATTRACTION-2, a Phase 3 randomized, double-blind, placebo-controlled clinical trial conducted in Japan, South Korea and Taiwan.
For comments and feedback contact: editorial@rttnews.com
Business News